Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma.

被引：0
|
作者：
Glassberg, Brittany
Khan, Sophia
Pemov, Alex
Hawley, Robert
Widemann, Brigitte C.
Khan, Javed
Glod, John
机构：
[1] NIH, Bldg 10, Bethesda, MD 20892 USA
[2] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15628
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Molecular diagnostics of hereditary medullary thyroid carcinoma
    Ziemnicka, Katarzyna
    Kaczmarek, Marta
    Hoppe-Golebiewska, Justyna
    Slomski, Ryszard
    Sowinski, Jerzy
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (04): : 175 - 177
  • [42] Characteristics and treatment of 35 patients affected by advanced medullary thyroid carcinoma.
    Koussis, H
    Scola, A
    Tonello, S
    Karahontzitis, P
    Pagetta, C
    Toniato, A
    Pelizzo, MR
    Casara, D
    Archonti, A
    Monfardini, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 514S - 514S
  • [43] Familial medullary thyroid carcinoma.: Usefulness of ultrasonography and colour-Doppler
    García, PF
    Deval, JC
    Doménech, SFM
    Sastre, ML
    REVISTA CLINICA ESPANOLA, 1998, 198 (11): : 745 - 748
  • [44] Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.
    Sun, Yongkun
    Chi, Yihebali
    Tang, Pingzhang
    Gao, Ming
    Ji, Qinghai
    Li, Zhendong
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Chen, Xiangjing
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Medullary thyroid carcinoma. Comments on a case seen in Dakar, Senegal.
    Sidibe, EH
    Diouf, R
    KaCisse, M
    Mendes, V
    Sow, AM
    SEMAINE DES HOPITAUX, 1996, 72 (31-32): : 989 - 992
  • [46] Molecular mutational analysis of medullary thyroid carcinoma
    Sheikh, H
    Cieply, K
    Tometsko, M
    Niehouse, L
    Aldeeb, D
    Swalsky, P
    Finkelstein, S
    Hunt, JL
    LABORATORY INVESTIGATION, 2003, 83 (01) : 109A - 109A
  • [47] Molecular mutational analysis of medullary thyroid carcinoma
    Sheikh, H
    Cieply, K
    Tometsko, M
    Niehouse, L
    Aldeeb, D
    Swasky, P
    Finkelstein, S
    Hunt, JL
    MODERN PATHOLOGY, 2003, 16 (01) : 109A - 109A
  • [48] Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
    Matsui, Ai
    Toda, Soji
    Murayama, Daisuke
    Iwasaki, Hiroyuki
    CASE REPORTS IN ENDOCRINOLOGY, 2022, 2022
  • [49] Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells
    Starenki, Dmytro
    Hong, Seung-Keun
    Wu, Pui-Kei
    Park, Jong-In
    CANCER BIOLOGY & THERAPY, 2017, 18 (07) : 473 - 483
  • [50] Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives
    Zhang, Ying
    Zheng, Wei-Hui
    Zhou, Shi-Hong
    Gu, Jia-Lei
    Yu, Qing
    Zhu, Yi-Zhou
    Yan, Yu-Jie
    Zhu, Zhi
    Shang, Jin-Biao
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
12345